<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns="http://purl.org/rss/1.0/"><channel rdf:about="http://www.neuropeptidesjournal.com//inpress?rss=yes"><title>Neuropeptides - Articles in Press</title><description>Neuropeptides RSS feed: Articles in Press. The aim of  Neuropeptides  is the rapid publication of original research and review articles, dealing with the structure, distribution, 
actions and functions of peptides in the central and peripheral nervous systems. The explosion of research activity in this field has 
led to the idenfication of numerous naturally occurring endogenous peptides which act as neurotransmitters, neuromodulators, or trophic 
factors, to mediate nervous system functions. Increasing numbers of non-peptide ligands of neuropeptide receptors have been developed, 
which act as agonists or antagonists in peptidergic systems. 
 The journal provides a unique opportunity of integrating the many disciplines 
involved in all neuropeptide research. The journal publishes articles on all aspects of the neuropeptide field, with particular emphasis 
on gene regulation of peptide expression, peptide receptor subtypes, transgenic and knockout mice with mutations in genes for neuropeptides 
and peptide receptors, neuroanatomy, physiology, behaviour, neurotrophic factors, preclinical drug evaluation, clinical studies, and 
clinical trials. 
 Original papers predominate. Manuscripts may be of any length, but must be complete studies; preliminary communications 
are not accepted. Review articles and hypothesis papers are welcomed, and will be evaluated in the same way as experimental papers. Authors 
intending to submit a review are advised to communicate their intentions to the Editor, to avoid possible duplication. 
 To order this 
journal online, visit    http://intl.elsevierhealth.com/journals/npep 
</description><link>http://www.neuropeptidesjournal.com//inpress?rss=yes</link><dc:publisher>Elsevier Inc.</dc:publisher><dc:language>en</dc:language><dc:rights> © 2010 Elsevier Ltd. All rights reserved. </dc:rights><prism:publicationName>Neuropeptides</prism:publicationName><prism:issn>0143-4179</prism:issn><prism:publicationDate>2010-07-20</prism:publicationDate><prism:copyright> © 2010 Elsevier Ltd. All rights reserved. </prism:copyright><prism:rightsAgent>healthpermissions@elsevier.com</prism:rightsAgent><items><rdf:Seq><rdf:li rdf:resource="http://www.neuropeptidesjournal.com/article/PIIS0143417910000673/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neuropeptidesjournal.com/article/PIIS0143417910000697/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neuropeptidesjournal.com/article/PIIS0143417910000685/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neuropeptidesjournal.com/article/PIIS0143417910000661/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neuropeptidesjournal.com/article/PIIS014341791000065X/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neuropeptidesjournal.com/article/PIIS0143417910000648/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neuropeptidesjournal.com/article/PIIS0143417910000521/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neuropeptidesjournal.com/article/PIIS014341791000051X/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neuropeptidesjournal.com/article/PIIS0143417910000508/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neuropeptidesjournal.com/article/PIIS0143417910000442/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neuropeptidesjournal.com/article/PIIS0143417910000491/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neuropeptidesjournal.com/article/PIIS014341791000048X/abstract?rss=yes"/><rdf:li rdf:resource="http://www.neuropeptidesjournal.com/article/PIIS0143417910000478/abstract?rss=yes"/></rdf:Seq></items></channel><item rdf:about="http://www.neuropeptidesjournal.com/article/PIIS0143417910000673/abstract?rss=yes"><title>The vasoactive intestinal peptide-receptor system is involved in human glioblastoma cell migration - Corrected Proof</title><link>http://www.neuropeptidesjournal.com/article/PIIS0143417910000673/abstract?rss=yes</link><description>Abstract: Glioblastoma multiforme (GBM) is the most aggressive form of brain tumor in adults. This cancer has an infiltrative nature and the median survival of patients is about one year. Vasoactive intestinal peptide (VIP) belongs to a structurally related family of polypeptides and is a major regulatory factor in the central and peripheral nervous systems. VIP regulates proliferation of astrocytes and of numerous cancer cell lines and modulates migration in prostatic and colonic cancer cell lines. Little is known about the involvement of VIP and its receptors (VIP-receptor system) in proliferation or migration of GBM cells. The effects of VIP, PACAP and of synthetic VIP antagonists were tested in two human GBM cell lines, M059K and M059J, established from two different parts of a single tumor. In these cells, the data revealed that the VIP-receptor system did not affect proliferation but controlled cell migration. Indeed, in M059K cells which express components of the VIP receptor system, the VIP receptor antagonists and a PACAP antibody enhanced migration. The VIP receptor antagonists increased generation of typical migration-associated processes: filopodia and lamellipodia, and activation of Rac1 and Cdc42 GTPases. Reciprocally, in M059J cells which poorly express the VIP-receptor system, treatments with the agonists VIP and PACAP resulted in decreased cell migration. Furthermore, the peptides appeared to act through a subclass of binding sites displaying an uncommon very high affinity for these ligands. Taken together, these observations suggest that components of the VIP-receptor system negatively regulate cell migration, thus showing potential anti-oncogenic properties.</description><dc:title>The vasoactive intestinal peptide-receptor system is involved in human glioblastoma cell migration - Corrected Proof</dc:title><dc:creator>Stéphanie Cochaud, Lucie Chevrier, Annie-Claire Meunier, Thomas Brillet, Corinne Chadéneau, Jean-Marc Muller</dc:creator><dc:identifier>10.1016/j.npep.2010.06.003</dc:identifier><dc:source>Neuropeptides (2010)</dc:source><dc:date>2010-07-20</dc:date><prism:publicationName>Neuropeptides</prism:publicationName><prism:publicationDate>2010-07-20</prism:publicationDate></item><item rdf:about="http://www.neuropeptidesjournal.com/article/PIIS0143417910000697/abstract?rss=yes"><title>Distinct distribution of corticotropin releasing factor receptors in human breast cancer - Corrected Proof</title><link>http://www.neuropeptidesjournal.com/article/PIIS0143417910000697/abstract?rss=yes</link><description>Abstract: The hypothalamic neuropeptide corticotropin releasing factor (CRF) has been found in several types of human cancer, where its biological role is not clarified. In experimental models of breast cancer CRF has been shown to exert anti-proliferative and other actions. Aim of the present study was to describe the expression of the two types of CRF receptors CRF1 and CRF2 in human breast tumors. Receptor expression was studied in breast biopsies from patients diagnosed for primary breast adenocarcinoma, obtained from the tumor and the adjacent benign tissue. Gene expression levels were evaluated by real-time PCR following reverse transcription of total RNA extracts. CRF1 transcripts were found in 23.1% of benign and in 23.1% of malignant biopsies. CRF2(a) was found in 22.2% of benign and 36.0% of malignant biopsies. Transcript levels of both receptors did not differ significantly between cancer and benign biopsies from the same tumor. No correlation was found between CRF receptor expression and patient histo/clinicopathological characteristics. Histological mapping using immunohistochemistry revealed positive CRF1 immunostaining in the cancerous implants and breast ducts, whereas CRF2 immunoreactivity was localized mainly in the perineural invasions. In conclusion, both CRF receptors were found in breast cancer and the respective benign adjacent tissue. The two CRF receptor proteins presented distinct distribution and subcellular localization, pointing into differing biological roles. CRF receptors could serve as targets of endogenous ligands expressed in the tumor microenvironment, regulating cancer growth.</description><dc:title>Distinct distribution of corticotropin releasing factor receptors in human breast cancer - Corrected Proof</dc:title><dc:creator>A. Kaprara, K. Pazaitou-Panayiotou, M.C. Chemonidou, T.C. Constantinidis, M. Lambropoulou, M. Koffa, A. Kiziridou, S. Kakolyris, A. Kortsaris, E. Chatzaki</dc:creator><dc:identifier>10.1016/j.npep.2010.06.005</dc:identifier><dc:source>Neuropeptides (2010)</dc:source><dc:date>2010-07-14</dc:date><prism:publicationName>Neuropeptides</prism:publicationName><prism:publicationDate>2010-07-14</prism:publicationDate></item><item rdf:about="http://www.neuropeptidesjournal.com/article/PIIS0143417910000685/abstract?rss=yes"><title>Impaired nocifensive behaviours and mechanical hyperalgesia, but enhanced thermal allodynia in pituitary adenylate cyclase-activating polypeptide deficient mice - Corrected Proof</title><link>http://www.neuropeptidesjournal.com/article/PIIS0143417910000685/abstract?rss=yes</link><description>Abstract: Pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) and its receptors (PAC1 and VPAC) have been shown in the spinal dorsal horn, dorsal root ganglia and sensory nerve terminals. Data concerning the role of PACAP in central pain transmission are controversial and we have recently published its divergent peripheral effects on nociceptive processes.The aim of the present study was to investigate acute somatic and visceral nocifensive behaviours, partial sciatic nerve ligation-evoked chronic neuropathic, as well as resiniferatoxin-induced inflammatory thermal and mechanical hyperalgesia in PACAP deficient (PACAP−/−) mice to elucidate its overall function in pain transmission. Neuronal activation was investigated with c-Fos immunohistochemistry.Paw lickings in the early (0–5min) and late (20–45min) phases of the formalin test were markedly reduced in PACAP−/− mice. Acetic acid-evoked abdominal contractions referring to acute visceral chemonociception was also significantly attenuated in PACAP knockout animals. In both models, the excitatory role of PACAP was supported by markedly greater c-Fos expression in the periaqueductal grey and the somatosensory cortex. In PACAP-deficient animals neuropathic mechanical hyperalgesia was absent, while c-Fos immunopositivity 20days after the operation was significantly higher. In this chronic model, these neurons are likely to indicate the activation of secondary inhibitory pathways. Intraplantarly injected resiniferatoxin-evoked mechanical hyperalgesia involving both peripheral and central processes was decreased, but thermal allodynia mediated by only peripheral mechanisms was increased in PACAP−/− mice.These data clearly demonstrate an overall excitatory role of PACAP in pain transmission originating from both exteroceptive and interoceptive areas, it is also involved in central sensitization. This can be explained by the signal transduction mechanisms of its identified receptors, both PAC1 and VPAC activation leads to neuronal excitation. In contrast, it is an inhibitory mediator at the level of the peripheral sensory nerve endings and decreases their sensitization to heat with presently unknown mechanisms.</description><dc:title>Impaired nocifensive behaviours and mechanical hyperalgesia, but enhanced thermal allodynia in pituitary adenylate cyclase-activating polypeptide deficient mice - Corrected Proof</dc:title><dc:creator>K. Sándor, V. Kormos, B. Botz, A. Imreh, K. Bölcskei, B. Gaszner, A. Markovics, J. Szolcsányi, N. Shintani, H. Hashimoto, A. Baba, D. Reglodi, Zs. Helyes</dc:creator><dc:identifier>10.1016/j.npep.2010.06.004</dc:identifier><dc:source>Neuropeptides (2010)</dc:source><dc:date>2010-07-12</dc:date><prism:publicationName>Neuropeptides</prism:publicationName><prism:publicationDate>2010-07-12</prism:publicationDate></item><item rdf:about="http://www.neuropeptidesjournal.com/article/PIIS0143417910000661/abstract?rss=yes"><title>Communication of substance P, calcitonin-gene-related neuropeptides and chemokine receptor 4 (CXCR4) in cord blood hematopoietic stem cells - Corrected Proof</title><link>http://www.neuropeptidesjournal.com/article/PIIS0143417910000661/abstract?rss=yes</link><description>Abstract: Background: Modulation of the expression of CXCR4 as a critical adhesion molecule on cord blood (CB) CD34+ cells could overcome delay following cord blood transplantation. Identification of beneficial effects of growth factors including cytokines and neuropeptides on CXCR4 expression would enable our understanding of this complicated network. Therefore, we aimed to assess the role of substance P (SP) and Calcitonin gene related peptide (CGRP) on CXCR4 levels.Material and methods: CD34+cells purified from CB were cultured in a serum-free liquid culture system. Different concentrations of SP and CGRP were used in combination with cytokine cocktail. Expression of CXCR4 at protein and genomic levels was assessed by flow cytometry and real time RT-PCR.Results: Our results indicate increased CXCR4+ CD34+ cells after 7days cultivation with SP and/or CGRP. Increased gene expression of the CXCR4 molecule was observed at 10−9M either SP or CGRP individually, by day 11 as compared to control group.Conclusions: Our study indicates that SP and CGRP induce CXCR4 protein expression in short term culture, and stimulate its expression. Consequently, the increased expression of CXCR4 could improve engraftment of CB CD34+ cells.</description><dc:title>Communication of substance P, calcitonin-gene-related neuropeptides and chemokine receptor 4 (CXCR4) in cord blood hematopoietic stem cells - Corrected Proof</dc:title><dc:creator>Somayeh Shahrokhi, Massoumeh Ebtekar, Kamran Alimoghaddam, Zohreh Sharifi, Seyed Hamidolah Ghaffari, Ali Akbar Pourfathollah, Maryam Kheirandish, Mahboobeh Mohseni, Ardeshir Ghavamzadeh</dc:creator><dc:identifier>10.1016/j.npep.2010.06.002</dc:identifier><dc:source>Neuropeptides (2010)</dc:source><dc:date>2010-07-05</dc:date><prism:publicationName>Neuropeptides</prism:publicationName><prism:publicationDate>2010-07-05</prism:publicationDate></item><item rdf:about="http://www.neuropeptidesjournal.com/article/PIIS014341791000065X/abstract?rss=yes"><title>Short- and long-term consequences of different early environmental conditions on central immunoreactive oxytocin and arginine vasopressin levels in male rats - Corrected Proof</title><link>http://www.neuropeptidesjournal.com/article/PIIS014341791000065X/abstract?rss=yes</link><description>Abstract: Numerous studies have provided evidence for an important role for the neuropeptides oxytocin (OT) and arginine vasopressin (AVP) in establishment of social behaviour early in life, such as mother–pup interactions. However, there are few reports examining the consequences of early-life experiences on OT and AVP in male offspring. We have used the maternal separation (MS) model to study the effect of different early environmental conditions in rats. The purpose was to study OT and AVP in rats subjected to prolonged daily MS (360min, MS360), short daily MS (15min, MS15) and conventional animal facility rearing (AFR) during postnatal days 1–21. In addition, the influence of the presence or absence of littermates during MS, i.e. litter-wise (l) or individual (i) MS, was assessed. The immunoreactive (ir) peptide levels were measured in the hypothalamus, amygdala and pituitary gland of 3 and 10weeks old male rats. Assessment in 3-week-old rats revealed that MS15 was associated with low ir OT levels in the hypothalamus and amygdala and high levels in the pituitary gland compared with the MS360 and AFR condition. In the amygdala, differences between groups were also detected in adulthood. MS studies commonly use either MS15 or AFR as a control for prolonged MS. The present results show differences in MS360 rats as compared to MS15 but not AFR rats. Consequently, comparisons between prolonged MS with either short periods of MS or AFR will generate divergent results, hence, making the outcome of MS difficult to compare between studies. Moreover, the different early environments had no effect on ir AVP levels. In conclusion, OT in the amygdala was most sensitive to MS. Besides both short- and long-term consequences, distinct effects were seen after litter and individual separation, respectively. We propose that environmentally induced alterations in OT transmission due to disrupted mother–pup interactions early in life may cause altered susceptibility to challenges later in life.</description><dc:title>Short- and long-term consequences of different early environmental conditions on central immunoreactive oxytocin and arginine vasopressin levels in male rats - Corrected Proof</dc:title><dc:creator>Sadia Oreland, Lisa Gustafsson-Ericson, Ingrid Nylander</dc:creator><dc:identifier>10.1016/j.npep.2010.06.001</dc:identifier><dc:source>Neuropeptides (2010)</dc:source><dc:date>2010-06-30</dc:date><prism:publicationName>Neuropeptides</prism:publicationName><prism:publicationDate>2010-06-30</prism:publicationDate></item><item rdf:about="http://www.neuropeptidesjournal.com/article/PIIS0143417910000648/abstract?rss=yes"><title>Involvement of preprotachykinin A gene-encoded peptides and the neurokinin 1 receptor in endotoxin-induced murine airway inflammation - Corrected Proof</title><link>http://www.neuropeptidesjournal.com/article/PIIS0143417910000648/abstract?rss=yes</link><description>Abstract: Tachykinins encoded by the preprotachykinin A (TAC1) gene such as substance P (SP) and neurokinin A (NKA) are involved in neurogenic inflammatory processes via predominantly neurokinins 1 and 2 (NK1 and NK2) receptor activation, respectively. Endokinins and hemokinins encoded by the TAC4 gene also have remarkable selectivity and potency for the NK1 receptors and might participate in inflammatory cell functions. The aim of the present study was to investigate endotoxin-induced airway inflammation and consequent bronchial hyper-reactivity in TAC1−/−, NK1−/− and also in double knockout (TAC1−/−/NK1−/−) mice.Sub-acute interstitial lung inflammation was evoked by intranasal Escherichia coli lipopolysaccharide (LPS) in the knockout mice and their wildtype C57BL/6 counterparts 24h before measurement. Respiratory parameters were measured with unrestrained whole body plethysmography. Bronchoconstriction was induced by inhalation of the muscarinic receptor agonist carbachol and Penh (enhanced pause) correlating with airway resistance was calculated. Lung interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) concentrations were measured with ELISA. Histological evaluation was performed and a composite morphological score was determined. Myeloperoxidase (MPO) activity in the lung was measured with spectrophotometry to quantify the number of infiltrating neutrophils/macrophages.Airway hyper-reactivity was significantly reduced in the TAC1−/− as well as the TAC1−/−/NK1−/− groups. However, LPS-induced histological inflammatory changes (perivascular/peribronchial oedema, neutrophil infiltration and goblet cell hyperplasia), MPO activity and TNF-α concentration were markedly diminished only in TAC1−/− mice. Interestingly, the concentrations of both cytokines, IL-1β and TNF-α, were significantly greater in the NK1−/− group.These data clearly demonstrated on the basis of histology, MPO and cytokine measurements that TAC1 gene-derived tachykinins, SP and NKA, play a significant role in the development of endotoxin-induced murine airway inflammation, but not solely via NK1 receptor activation. However, in inflammatory bronchial hyper-responsiveness other tachykinins, such as hemokinin-1 acting through NK1 receptors also might be involved.</description><dc:title>Involvement of preprotachykinin A gene-encoded peptides and the neurokinin 1 receptor in endotoxin-induced murine airway inflammation - Corrected Proof</dc:title><dc:creator>Zsuzsanna Helyes, Krisztián Elekes, Katalin Sándor, István Szitter, László Kereskai, Erika Pintér, Ágnes Kemény, János Szolcsányi, Lynn McLaughlin, Sylvia Vasiliou, Anja Kipar, Andreas Zimmer, Stephen P. Hunt, James P. Stewart, John P. Quinn</dc:creator><dc:identifier>10.1016/j.npep.2010.05.004</dc:identifier><dc:source>Neuropeptides (2010)</dc:source><dc:date>2010-06-25</dc:date><prism:publicationName>Neuropeptides</prism:publicationName><prism:publicationDate>2010-06-25</prism:publicationDate></item><item rdf:about="http://www.neuropeptidesjournal.com/article/PIIS0143417910000521/abstract?rss=yes"><title>Opposite control of body temperature by NPFF1 and NPFF2 receptors in mice - Corrected Proof</title><link>http://www.neuropeptidesjournal.com/article/PIIS0143417910000521/abstract?rss=yes</link><description>Abstract: Neuropeptide FF (NPFF) is a neurotransmitter known to modulate opioid functions. This study investigates the effects of RF9, a new antagonist of NPFF receptors, on the roles of NPFF1 and NPFF2 receptors in thermoregulation in mice. RF9 (10nmol) injected into the third ventricle did not modify the body temperature as compared to saline, but it completely antagonized the hypothermic effects of 10nmol NPVF, a NPFF1 selective agonist, as well as the hyperthermic actions of dNPA (5nmol), a NPFF2 selective agonist. The use of a specific antagonist demonstrates here that central NPFF1 and NPFF2 receptors control in an opposite manner the body temperature in mice.</description><dc:title>Opposite control of body temperature by NPFF1 and NPFF2 receptors in mice - Corrected Proof</dc:title><dc:creator>Lionel Moulédous, Florent Barthas, Jean-Marie Zajac</dc:creator><dc:identifier>10.1016/j.npep.2010.05.003</dc:identifier><dc:source>Neuropeptides (2010)</dc:source><dc:date>2010-06-16</dc:date><prism:publicationName>Neuropeptides</prism:publicationName><prism:publicationDate>2010-06-16</prism:publicationDate><prism:section>SHORT COMMUNICATION</prism:section></item><item rdf:about="http://www.neuropeptidesjournal.com/article/PIIS014341791000051X/abstract?rss=yes"><title>Vasoactive intestinal peptide induces vascular endothelial growth factor production in human HaCaT keratinocytes via MAPK pathway - Corrected Proof</title><link>http://www.neuropeptidesjournal.com/article/PIIS014341791000051X/abstract?rss=yes</link><description>Abstract: Psoriasis is a chronic skin disease characterized by abnormal keratinocyte proliferation and differentiation, inflammation, and angiogenesis. Although dysfunction of the immune system is known to be an important factor in the pathogenesis of psoriasis, there is also strong evidence that psychological stresses are involved. Neuropeptides are thought to be main mediators of neurogenic inflammation, presumably involved in the pathogenesis of psoriasis. Vasoactive intestinal peptide (VIP) is one of the major neuropeptides in human and rodent skin. In the present study, we examined the effect and mechanism of VIP on vascular endothelial growth factor (VEGF) production by HaCaT cells which is a spontaneous, immortalized, human keratinocyte cell line. Our data indicate the mRNA and protein levels of VEGF by VIP were increased in a concentration-dependent manner. However, this increase was abrogated by pretreatment with an extracellular signal-regulated kinase (ERK) inhibitor PD98059 or p38MAPK inhibitor SB203580; pretreatment with c-Jun N-terminal kinase (JNK) inhibitor SP600125 did not attenuate the effects of VIP on the expression of VEGF. In addition, VIP treatment induced rapid phosphorylation of ERK1/2 and p38MAPK, and PD98059 and SB203580 were able to inhibit VIP-induced phosphorylation of ERK1/2 and p38MAPK, respectively. These results suggest that VIP increases the expression of VEGF through the ERK1/2 and p38MAPK signaling pathway in human HaCaT cells.</description><dc:title>Vasoactive intestinal peptide induces vascular endothelial growth factor production in human HaCaT keratinocytes via MAPK pathway - Corrected Proof</dc:title><dc:creator>Xiao-Jing Yu, Xiao-Hong Ren, Yong-Hao Xu, La-Mei Chen, Chun-Lei Zhou, Chun-Yang Li</dc:creator><dc:identifier>10.1016/j.npep.2010.05.002</dc:identifier><dc:source>Neuropeptides (2010)</dc:source><dc:date>2010-06-04</dc:date><prism:publicationName>Neuropeptides</prism:publicationName><prism:publicationDate>2010-06-04</prism:publicationDate></item><item rdf:about="http://www.neuropeptidesjournal.com/article/PIIS0143417910000508/abstract?rss=yes"><title>Effects of acute ethanol administration on methionine–enkephalin expression and release in regions of the rat brain - Corrected Proof</title><link>http://www.neuropeptidesjournal.com/article/PIIS0143417910000508/abstract?rss=yes</link><description>Abstract: The dopaminergic mesolimbic system plays a key role in mediating the reinforcing properties of ethanol and other drugs of abuse. Ethanol reinforcement and high alcohol drinking behaviour have been suggested to involve the ethanol-induced activation of endogenous opioid systems. Ethanol may alter opioidergic transmission at different levels, including opioid peptide biosynthesis and release, as well as binding to opioid receptors. The aim of this work was to investigate the effects of different ethanol doses on methionine–enkephalin (Met-enk) release from the rat nucleus accumbens (NAcc). Ethanol effects were also studied on Met-enk content in the NAcc, prefrontal cortex (PFC) and caudate-putamen (CP). Met-enk release was studied by microdialysis in Wistar anesthetized rats and peptide concentrations were quantitated by radioimmunoassay. Ethanol was administered by intraperitoneal injection after a 2-h basal release period. Ethanol doses of 0.5, 1 and 2.5g/kg induced a 2.7-, 4.9- and 3.4-fold increase in Met-enk release from the NAcc. However, ethanol responses followed different kinetics, with earliest effects observed with the highest ethanol dose. In comparison, a 2.5-fold increase in peptide release was produced by 100mM KCl. Ethanol, at a dose of 2.5g/kg, induced a significant 66.7% decrease in Met-enk content in the NAcc, as well as a 76.4% reduction in peptide levels in the CP. Lower ethanol doses did not alter Met-enk content in these regions. On the other hand, an ethanol dose of 0.5g/kg produced a non-significant decrease in Met-enk levels in the PFC. Our results suggest that ethanol-induced changes in enkephalin expression and release in regions of the mesocorticolimbic and nigrostriatal pathways could be involved in ethanol central effects. Released enkephalins by ethanol may modulate the dopaminergic activity of mesolimbic neurons and play a critical role in ethanol reinforcement mechanisms.</description><dc:title>Effects of acute ethanol administration on methionine–enkephalin expression and release in regions of the rat brain - Corrected Proof</dc:title><dc:creator>M. Méndez, I.G. Barbosa-Luna, J.M. Pérez-Luna, A. Cupo, J. Oikawa</dc:creator><dc:identifier>10.1016/j.npep.2010.05.001</dc:identifier><dc:source>Neuropeptides (2010)</dc:source><dc:date>2010-06-02</dc:date><prism:publicationName>Neuropeptides</prism:publicationName><prism:publicationDate>2010-06-02</prism:publicationDate></item><item rdf:about="http://www.neuropeptidesjournal.com/article/PIIS0143417910000442/abstract?rss=yes"><title>Conditional stimulation by galanin of saccharin and ethanol consumption under free and response contingent access - Corrected Proof</title><link>http://www.neuropeptidesjournal.com/article/PIIS0143417910000442/abstract?rss=yes</link><description>Abstract: Prior research has shown that the neuropeptide galanin strongly stimulates food intake in sated rats when food is made freely available. However, when access to food is made contingent upon lever pressing on a reinforcement schedule, no such stimulation occurs. This dissociation is consistent with the theorized “behavioral energizing” function of the ascending mesolimbic dopamine system, which purports that this ascending dopamine system is involved in only the goal directed effort maintaining (appetitive) and not the hedonic (consummatory) aspects of reward. Further, these results suggest that galanin may play an inhibitory role therein, or itself may be inhibited by mesolimbic dopamine activity underlying instrumental behavior. Prior research into this phenomenon has only utilized caloric foods or water, so the current work assessed the generality of this finding by determining if a similar dissociation also applies to commodities with other properties. For the present experiments, two commodities which varied in the dimensions of palatability and caloric load but which are both known to serve as reinforcers in other settings were chosen. In the first experiment, under the current single commodity free consumption test conditions shown to be sensitive to galanin effects of food and water consumption, galanin did not significantly alter the consumption of caloric laden but poorly palatable 7% alcohol solution. However, in the second experiment, galanin significantly increased free consumption of a highly palatable but non-caloric 0.2% saccharin solution but not when operant responding was required for access to saccharin, extending the basic appetitive-consummatory dissociation observed for food. Taken together, these results suggest that the gustatory properties may be a specific factor involved in galanin stimulation of free consumption, and that there may be a continuum of influence of galanin based on the relative “elasticity” of the commodities as reinforcers.</description><dc:title>Conditional stimulation by galanin of saccharin and ethanol consumption under free and response contingent access - Corrected Proof</dc:title><dc:creator>I.M. McNamara, J.K. Robinson</dc:creator><dc:identifier>10.1016/j.npep.2010.04.003</dc:identifier><dc:source>Neuropeptides (2010)</dc:source><dc:date>2010-06-01</dc:date><prism:publicationName>Neuropeptides</prism:publicationName><prism:publicationDate>2010-06-01</prism:publicationDate></item><item rdf:about="http://www.neuropeptidesjournal.com/article/PIIS0143417910000491/abstract?rss=yes"><title>Somatostatin-28 modulates prepulse inhibition of the acoustic startle response, reward processes and spontaneous locomotor activity in rats - Corrected Proof</title><link>http://www.neuropeptidesjournal.com/article/PIIS0143417910000491/abstract?rss=yes</link><description>Abstract: Somatostatins have been shown to be involved in the pathophysiology of motor and affective disorders, as well as psychiatric disorders, including schizophrenia. We hypothesized that in addition to motor function, somatostatin may be involved in somatosensory gating and reward processes that have been shown to be dysregulated in schizophrenia. Accordingly, we evaluated the effects of intracerebroventricular administration of somatostatin-28 on spontaneous locomotor and exploratory behavior measured in a behavioral pattern monitor, sensorimotor gating, prepulse inhibition (PPI) of the acoustic startle reflex, and brain reward function (measured in a discrete trial intracranial self-stimulation procedure) in rats. Somatostatin-28 decreased spontaneous locomotor activity during the first 10min of a 60min testing session with no apparent changes in the exploratory activity of rats. The highest somatostatin-28 dose (10μg/5μl/side) induced PPI deficits with no effect on the acoustic startle response or startle response habituation. The somatostatin-induced PPI deficit was partially reversed by administration of SRA-880, a selective somatostatin 1 (sst1) receptor antagonist. Somatostatin-28 also induced elevations in brain reward thresholds, reflecting an anhedonic-like state. The non-peptide sst1 receptor antagonist SRA-880 had no effect on brain reward function under baseline conditions. Altogether these findings suggest that somatostatin-28 modulates PPI and brain reward function but does not have a robust effect on spontaneous exploratory activity. Thus, increases in somatostatin transmission may represent one of the neurochemical mechanisms underlying anhedonia, one of the negative symptoms of schizophrenia, and sensorimotor gating deficits associated with cognitive impairments in schizophrenia patients.</description><dc:title>Somatostatin-28 modulates prepulse inhibition of the acoustic startle response, reward processes and spontaneous locomotor activity in rats - Corrected Proof</dc:title><dc:creator>Svetlana Semenova, Daniel Hoyer, Mark A. Geyer, Athina Markou</dc:creator><dc:identifier>10.1016/j.npep.2010.04.008</dc:identifier><dc:source>Neuropeptides (2010)</dc:source><dc:date>2010-06-01</dc:date><prism:publicationName>Neuropeptides</prism:publicationName><prism:publicationDate>2010-06-01</prism:publicationDate></item><item rdf:about="http://www.neuropeptidesjournal.com/article/PIIS014341791000048X/abstract?rss=yes"><title>Serum hepatocyte growth factor levels and the effects of antidepressants in panic disorder - Corrected Proof</title><link>http://www.neuropeptidesjournal.com/article/PIIS014341791000048X/abstract?rss=yes</link><description>Abstract: Previous animal studies have suggested that hepatocyte growth factor (HGF) could be associated with depression- and anxiety-related behaviors. Our aim was to relate serum HGF levels with State-Trait Anxiety Inventory (STAI), Profile of Mood State (POMS), and Revised NEO Personality Inventory (NEO-PI-R) scores in patients with panic disorder (with or without agoraphobia) and healthy controls. We examined 67 patients with panic disorders and 97 controls. Patients were split into two groups according to whether they exhibited a 50% improvement in test scores (good/high response group: n=26) or not (poor/low response group: n=41). In both healthy control and panic disorder individuals, there were no significant associations between HGF serum levels and STAI or NEO-PI-R scores. However, there was a significant correlation between serum HGF levels and fatigue in healthy control subjects in as scored by POMS testing. HGF concentration in the good/high response group was significantly elevated compared to both the low/poor response group (p&lt;0.01) and the control group (p&lt;0.01). HGF levels in the poor response group did not differ from the control group (p=0.48). These results indicate that increased serum HGF levels might be a requirement for antidepressant efficacy in patients with panic disorders.</description><dc:title>Serum hepatocyte growth factor levels and the effects of antidepressants in panic disorder - Corrected Proof</dc:title><dc:creator>Masayuki Kanehisa, Yoshinobu Ishitobi, Tomoko Ando, Shizuko Okamoto, Yoshihiro Maruyama, Kentaro Kohno, Taiga Ninomiya, Haruka Higuma, Yoshihiro Tanaka, Jusen Tsuru, Hiroaki Hanada, Kensuke Kodama, Jotaro Akiyoshi</dc:creator><dc:identifier>10.1016/j.npep.2010.04.007</dc:identifier><dc:source>Neuropeptides (2010)</dc:source><dc:date>2010-05-19</dc:date><prism:publicationName>Neuropeptides</prism:publicationName><prism:publicationDate>2010-05-19</prism:publicationDate></item><item rdf:about="http://www.neuropeptidesjournal.com/article/PIIS0143417910000478/abstract?rss=yes"><title>Effects of rat/mouse hemokinin-1, human hemokinin-1 and human hemokinin-1(4-11), mammalian tachykinin peptides, on rate and perfusion pressure in the isolated guinea pig heart - Corrected Proof</title><link>http://www.neuropeptidesjournal.com/article/PIIS0143417910000478/abstract?rss=yes</link><description>Abstract: Rat/mouse hemokinin-1 (r/m HK-1), human hemokinin-1 (h HK-1) and human hemokinin-1(4-11) (h HK-1(4-11)) are members of the tachykinin family. In the present study, the coronary vascular activities and cardiac functions of r/m HK-1, h HK-1 and h HK-1(4-11) were investigated in isolated, spontaneously beating guinea pig hearts. Bolus injections of r/m HK-1 caused decrease in perfusion pressure indicative of coronary vasodilation, which was primarily due to the action on tachykinin NK1 receptors on vascular endothelial cells, causing the release of nitric oxide that relaxed the coronary vessels. H HK-1 caused biphasic perfusion pressure changes that were coronary vasodilation followed by coronary vasoconstriction. The mechanisms involved in the vasodilation induced by h HK-1 were similar to that of r/m HK-1 while the mechanisms for coronary vasoconstriction were mediated through the activation of tachykinin NK2 receptors on coronary sympathetic neurons to release catecholamines. H HK-1(4-11) only produced coronary vasoconstriction and the mechanisms involved in this effect were similar to that of h HK-1 in vasoconstriction. Moreover, r/m HK-1 and h HK-1 produced similar decreases in heart rate indicative of negative chronotropic responses and the decreases were mainly mediated through the activation of tachykinin NK1 receptors to release ACh acting on muscarinic receptors. H HK-1(4-11) also produced negative chronotropic response, which was mainly mediated through tachykinin NK2 receptors and muscarinic receptors. Our present results provide evidence that all of the three tachykinins could influence cardiac function and coronary vascular activity in the isolated guinea pig heart.</description><dc:title>Effects of rat/mouse hemokinin-1, human hemokinin-1 and human hemokinin-1(4-11), mammalian tachykinin peptides, on rate and perfusion pressure in the isolated guinea pig heart - Corrected Proof</dc:title><dc:creator>Zi-Qing Kong, Wen-Le Yang, Yan Tao, Xiao-Mei Shi, Cai-Yun Fu, Rui-Fei Zhao, Rui Wang</dc:creator><dc:identifier>10.1016/j.npep.2010.04.006</dc:identifier><dc:source>Neuropeptides (2010)</dc:source><dc:date>2010-05-17</dc:date><prism:publicationName>Neuropeptides</prism:publicationName><prism:publicationDate>2010-05-17</prism:publicationDate></item></rdf:RDF>